X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
SUVEN LIFE Fact Sheet, SUVEN LIFE Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE Fact Sheet   (SVNP)

Here is the latest financial fact sheet of SUVEN LIFE. For more details, see the SUVEN LIFE quarterly results and SUVEN LIFE share price and chart. For a sector overview, read our pharmaceuticals sector report.

SUVEN LIFE Price History

Price Rs 171.6
Mkt Cap Rs m 20,042
Vol '000 24.3
P/E X 17.3
P/CF X 17.9
EPS (TTM) Rs 9.9
% ch % 0.4
No. of shares m 116.83
% ch week % -0.3
% ch 1-mth % -4.6
% ch 12-mth % -17.3
52 week H/L Rs 213.9/151.1
(As on Jul 21, 2017 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

SUVEN LIFE Financials

No. of Mths
Year Ending
12
Mar-12
12
Mar-13
12
Mar-14
12
Mar-15
12
Mar-16
5-Yr Chart
Click to enlarge
SUVEN LIFE EQUITY SHARE DATA
High Rs263583323339 
Low Rs12142272144 
Sales per share (Unadj.) Rs17.522.143.740.939.2 
Earnings per share (Unadj.) Rs1.22.612.38.57.5 
Diluted earnings per shareRs1.22.612.39.38.1 
Cash flow per share (Unadj.) Rs1.73.313.19.58.8 
Dividends per share (Unadj.) Rs0.300.300.500.602.00 
Adj. dividends per shareRs0.300.300.500.652.18 
Dividend yield (eoy) %1.61.20.90.30.8 
Book value per share (Unadj.) Rs10.913.222.643.949.0 
Adj. book value per shareRs10.913.222.647.953.4 
Shares outstanding (eoy) m116.73116.82116.82127.28127.28 
Bonus/Rights/Conversions  -OI-IS- 
Price / Sales ratio x1.11.11.24.86.2 
Avg P/E ratio x15.19.24.323.132.4 
P/CF ratio (eoy) x10.77.44.020.827.5 
Price / Book Value ratio x1.71.82.34.54.9 
Dividend payout %24.411.44.17.026.8 
Avg Mkt Cap Rs m2,1712,8506,15625,10030,732 
No. of employees `000NANANA0.91.0 
Total wages/salary Rs m228254314365416 
Avg. sales/employee Rs ThNMNMNM5,912.15,236.1 
Avg. wages/employee Rs ThNMNMNM414.4436.5 
Avg. net profit/employee Rs ThNMNMNM1,234.4995.5 
SUVEN LIFE INCOME DATA
Net Sales Rs m2,0422,5795,1035,2094,995 
Other income Rs m19103086194 
Total revenues Rs m2,0612,5895,1335,2945,189 
Gross profit Rs m2325322,1911,5951,233 
Depreciation Rs m607988118167 
Interest Rs m991351054754 
Profit before tax Rs m913292,0271,5161,205 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m-5220586428255 
Profit after tax Rs m1443081,4421,088950 
Gross profit margin %11.320.642.930.624.7 
Effective tax rate %-57.16.128.928.221.2 
Net profit margin %7.012.028.220.919.0 
SUVEN LIFE BALANCE SHEET DATA
Current assets Rs m1,0491,3692,8064,7704,986 
Current liabilities Rs m1,0071,0741,5511,2741,042 
Net working cap to sales %2.111.424.667.179.0 
Current ratio x1.01.31.83.74.8 
Inventory Days Days8376565761 
Debtors Days Days4534472839 
Net fixed assets Rs m1,5611,6571,9212,7903,126 
Share capital Rs m117117117127127 
"Free" reserves Rs m7581,0262,1253,0743,717 
Net worth Rs m1,2751,5452,6455,5936,236 
Long term debt Rs m550642377615432 
Total assets Rs m2,8503,2764,8667,7318,079 
Interest coverage x1.93.420.333.223.2 
Debt to equity ratio x0.40.40.10.10.1 
Sales to assets ratio x0.70.81.00.70.6 
Return on assets %8.513.531.814.712.4 
Return on equity %11.320.054.519.415.2 
Return on capital %10.421.270.625.218.9 
Exports to sales %89.084.590.188.187.5 
Imports to sales %16.515.19.411.612.2 
Exports (fob) Rs m1,8182,1804,6004,5904,371 
Imports (cif) Rs m337389482602611 
Fx inflow Rs m1,8182,1804,7524,7794,666 
Fx outflow Rs m430515608855942 
Net fx Rs m1,3881,6654,1433,9243,724 
SUVEN LIFE CASH FLOW
From Operations Rs m 338 307 1,212 1,429 922 
From Investments Rs m -320 -147 -355 -1,105 -619 
From Financial Activity Rs m -18 26 -382 1,791 -698 
Net Cashflow Rs m -1 186 474 2,116 -396 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 63.4%
Foreign collaborators 0.0%
Indian inst/Mut Fund 0.0%
FIIs 0.0%
ADR/GDR 0.0%
Free float 36.5%
Shareholders 37,287
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF SDE Serene Chambers, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500 034
E-MAIL investorservices@suven.com WEB www.suven.com
TELEPHONE (040) 2354 3311 FAX (040) 2354 1152
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Karvy Computershare, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR Karvy & Company
COMP SEC: K. Hanumantha Rao YEAR OF INC: 1989 BSE CODE: 530239 FV (Rs): 1 DIV YIELD (%): 1.3

More Pharmaceuticals Company Fact Sheets:   ELDER PHARMA  CIPLA  AJANTA PHARMA  TTK HEALTHCARE  PFIZER  

Compare SUVEN LIFE With:   ELDER PHARMA  CIPLA  AJANTA PHARMA  TTK HEALTHCARE  PFIZER  

Compare SUVEN LIFE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Stronger Euro Drags European Markets(RoundUp)

The strength of the euro does appear to be acting as a bit of a headwind for European stocks as they look to close the week sharply lower in contrast to the performance of UK and US stocks this week.

Views on news

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

More Views on News

Most Popular

Post Demonetisation Real Estate Sales Have Collapsed, But Prices Haven't(Vivek Kaul's Diary)

Jul 11, 2017

While sales have fallen dramatically, net net home prices continue to hold on.

Ride the Bull Wave with These Perfect Proxies to India's Growth Story(The 5 Minute Wrapup)

Jul 15, 2017

The secret of spotting multibaggers before they become a hit.

The New Pharma Rally Starts NOW(Daily Profit Hunter)

Jul 12, 2017

The most hated sector is offering the best trading opportunity. Are you ready?

All You Need To Know To e-File Your Income Tax Returns(Outside View)

Jul 12, 2017

The Income Tax return filing deadline is drawing near; if you have not already filed your taxes, here's how to do it.

The Impact of GST On Banking transactions, Insurance, and Investments(Outside View)

Jul 11, 2017

PersonalFN explains how GST impacts your insurance premiums, investments, and banking transactions.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK SUVEN LIFE

  • Track your investment in SUVEN LIFE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFE

SUVEN LIFE - ALEMBIC PHARMA COMPARISON

COMPARE SUVEN LIFE WITH

MARKET STATS